Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TIMOLOL MALEATE

All products: not a benefit

Other products in the same Health Canada class (S01ED) — coverage varies; not interchangeable

  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit
  • Brimonidine + timolol (Apo-Brimonidine-Timop): limited Use 310, 393
  • Brinzolamide + timolol (Azarga): limited Use 310, 393
  • Dorzolamide + timolol (Cosopt): limited Use 310, 393
  • Latanoprost + timolol (Xalacom): limited Use 310, 393

11 more in the class list below

Timoptic · DIN 00451193 · 0.25% · Oph Sol

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-11-22 — choose a marketed DIN from the same-category list.Discontinued 2006-11-22 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-11-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-11-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Timoptic · DIN 00451193 Manufacturer: Merck Frosst Canada Ltd.; listing date 1996-10-01 Health Canada: Cancelled post market since 2006-11-22 · brand TIMOPTIC · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.25 % · company Merck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Timoptic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3185 · Verify on the e-Formulary ↗ (DIN 00451193)

Source record
DIN 00451193: Timoptic Raw flags: notABenefit=Y, sec3=Y Item: 523600021; group id 641; item number 1616; lccId None; manufacturer id MFC Source form: Oph Sol; strength: 0.25% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00451193 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3185 Therapeutic Notes (formulary) Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma. Highest historical DBP for this product is $2.7650.
Interchangeable products
Sandoz Timolol · DIN 02166712 · $2.3503
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2006-11-22 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE 52:36 Other Eye, Ear, Nose and Throat Agents

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE & TIMOLOL MALEATE

· 1 products · Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk

DORZOLAMIDE HCL & TIMOLOL MALEATE

· 11 products · Limited Use, codes 310, 393 · strengths: 2% & 0.5% · Oph Sol, Oph Sol-0.2mL Pk

LATANOPROST & TIMOLOL MALEATE

· 9 products · Limited Use, codes 310, 393 · strengths: 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk

TIMOLOL MALEATE & TRAVOPROST

· 4 products · Listed, not a benefit (1), Limited Use, codes 310, 393 (3) · strengths: 0.5% & 0.004% · Oph Sol, Oph Sol-5mL Pk

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: elevated intraocular pressure
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BIMATOPROST · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7)  the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension PM: https://pdf.hres.ca/dpd_pm/00049647.PDF; date January 28, 2019; DIN 02429063; fetched 2026-09-10 Product monograph BRINZOLAMIDE · Limited Use, codes 171, 172, 387 • the treatment of elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma. PM: https://pdf.hres.ca/dpd_pm/00069562.PDF; date OCT 23, 1998; DIN 02238873; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS TIMOPTIC® (timolol maleate ophthalmic solution, USP) is indicated for:  the reduction of elevated intraocular pressure 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada, therefore, an indication for pediatric use has not been authorized. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from experience in geriatric populations does not suggests significant differences in safety and effectiveness. https://pdf.hres.ca/dpd_pm/00067983.PDF PM date: OCT 28, 2016 Source product: TIMOPTIC; DIN 00451207; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Timoptic: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026